News

Cardiovascular artificial intelligence (AI) company Anumana has received U.S. Food and Drug Administration (FDA) clearance for its ECG-AI algorithm for cardiac…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™…

AbstractGlypican-4 (GPC-4), an endothelial cell surface protein, is released into the circulation in the context of ischemia, inflammation, neurohumoral activity,…

Hereditary transthyretin amyloidosis is an autosomal dominant disease caused by mutations in the TTR gene, which encodes the protein transthyretin. It is…

Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…

In Las Vegas, Nevada, United States, DelveInsight's assessment reveals that globally, there are 10 key companies actively developing treatment therapies for AL…

Cardiac transthyretin amyloidosis (ATTR-CA) is caused by myocardial deposition of misfolded transthyretin, leading to progressive heart failure. Disease pathology,…

Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates…

AbstractTransthyretin (TTR) amyloid cardiomyopathy occurs when stable TTR, normally a 4-protein tetramer, becomes misfolded and aggregates to form amyloid fibrils…

NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in…